We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
+14.04%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$229M
AUM Growth
+$34.9M
(+18%)
Cap. Flow
+$13.6M
Cap. Flow
% of AUM
5.94%
Top 10 Holdings %
Top 10 Hldgs %
57.76%
Holding
47
New
12
Increased
9
Reduced
17
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$14.1M |
| 2 |
Cigna
CI
|
+$11.8M |
| 3 |
UroGen Pharma
URGN
|
+$6.62M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$6.05M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$4.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$8.21M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$6.42M |
| 3 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$5.77M |
| 4 |
HNGR
Hanger Inc.
HNGR
|
+$5.07M |
| 5 |
Viking Therapeutics
VKTX
|
+$4.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.63% |
| 2 | Technology | 3.03% |
| 3 | Industrials | 1.92% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cigna
CI
$76.6B
| $22.2M | 9.71% |
138,000
+64,700
| +88% | +$11.8M |
|
|
HNGR
2
DELISTED
Hanger Inc.
HNGR
| $17.8M | 7.78% |
933,548
-255,851
| -22% | -$5.07M |
|
3
Zimmer Biomet
ZBH
$17.7B
| $15.8M | 6.9% |
127,205
+20,724
| +19% | +$2.36M |
|
|
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $15M | 6.57% |
175,700
-77,300
| -31% | -$6.42M |
|
|
5
Bristol-Myers Squibb
BMY
$127B
| $13.5M | 5.91% |
+283,000
| New | +$14.1M |
|
|
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $11.3M | 4.95% |
252,500
-25,150
| -9% | -$1.15M |
|
|
WCG
7
DELISTED
Wellcare Health Plans, Inc.
WCG
| $11M | 4.8% |
40,700
-9,300
| -19% | -$2.4M |
|
8
Iovance Biotherapeutics
IOVA
$2.23B
| $8.72M | 3.82% |
917,080
-145,420
| -14% | -$1.41M |
|
|
ALBO
9
DELISTED
Albireo Pharma Inc
ALBO
| $8.69M | 3.8% |
269,836
-310
| -0.1% | -$8.35K |
|
|
NVRO
10
DELISTED
NEVRO CORP.
NVRO
| $8.05M | 3.52% |
+128,765
| New | +$6.05M |
|
|
EFOR
11
Everforth Inc
EFOR
$845M
| $6.93M | 3.03% |
109,116
+21,416
| +24% | +$1.34M |
|
12
Assembly Biosciences
ASMB
$506M
| $6.19M | 2.71% |
26,201
+3,206
| +14% | +$812K |
|
|
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.19M | 2.71% |
249,389
+189,289
| +315% | +$4.75M |
|
|
14
UroGen Pharma
URGN
$2B
| $5.83M | 2.55% |
+157,862
| New | +$6.62M |
|
15
Aldeyra Therapeutics
ALDX
$91.7M
| $5.27M | 2.3% |
583,300
+178,837
| +44% | +$1.52M |
|
16
BioMarin Pharmaceuticals
BMRN
$11.5B
| $5.1M | 2.23% |
57,384
-45,616
| -44% | -$4.23M |
|
|
EXAS
17
PUT
DELISTED
Exact Sciences
EXAS
| $4.72M | 2.07% |
+54,500
| New | +$4.64M |
|
|
SBBP
18
DELISTED
Strongbridge Biopharma plc.
SBBP
| $4.65M | 2.03% |
933,876
-4,024
| -0.4% | -$19.8K |
|
|
WAGE
19
DELISTED
WageWorks, Inc.
WAGE
| $4.38M | 1.92% |
+115,926
| New | +$3.78M |
|
|
NVRO
20
CALL
DELISTED
NEVRO CORP.
NVRO
| $4.38M | 1.91% |
+70,000
| New | +$3.29M |
|
|
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $4.2M | 1.84% |
61,442
-2,407
| -4% | -$154K |
|
22
Centene
CNC
$31.3B
| $4.16M | 1.82% |
78,400
+28,400
| +57% | +$1.72M |
|
23
Tempest Therapeutics
TPST
$14.8M
| $4.06M | 1.78% |
1,389
+72
| +5% | +$159K |
|
24
Indaptus Therapeutics
INDP
$348M
| $3.98M | 1.74% |
242
-60
| -20% | -$1.05M |
|
25
Gyre Therapeutics
GYRE
$662M
| $3.93M | 1.72% |
64,560
+2,307
| +4% | +$148K |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q1 2019 Portfolio in Review
As of Q1 2019, Prosight Management held 47 positions worth $229M, up 18% from $194M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Prosight Management deployed $13.6M of net new capital in Q1 2019, opening 12 new positions and adding to 9 existing holdings. Its largest new stake was Bristol-Myers Squibb: 283,000 shares worth $13.5M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 91% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $6.42M trimmed.
- Prosight Management's largest Q1 2019 buy was Bristol-Myers Squibb: 283,000 shares worth $13.5M.
- Prosight Management added most to Cigna in Q1 2019, an estimated $11.8M increase.
- Prosight Management's biggest Q1 2019 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $6.42M.
- Prosight Management fully exited Allergan plc in Q1 2019, selling an estimated $8.21M.
- Prosight Management's ten largest holdings make up 58% of its $229M portfolio in Q1 2019.
- Prosight Management opened 12 new positions and closed 9 in Q1 2019.
- Prosight Management's portfolio value rose 18% quarter-over-quarter to $229M.
Based on Prosight Management's 13F filing for Q1 2019, filed 15 May 2019.